An evaluation of the FDA adverse event reporting system and the potential for reporting bias

被引:5
|
作者
Monnot, Andrew D. [1 ]
Fung, Ernest S. [2 ]
Compoginis, Goli S. [3 ]
Towle, Kevin M. [1 ]
机构
[1] Cardno ChemRisk, 235 Pine St,Suite 2300, San Francisco, CA 94104 USA
[2] Cardno ChemRisk, Aliso Viejo, CA USA
[3] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
关键词
adverse event reporting; cosmetics; news media;
D O I
10.1111/jocd.14065
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The FDA maintains the Adverse Event Reporting System (CAERS) database, which contains product complaint reports for foods, dietary supplements, and cosmetics. Product line perception and subsequent adverse event reporting may be impacted by negative media attention. Methods The purpose of this analysis was to use the CAERS database to analyze temporal trends in adverse event reporting before and after media coverage of alleged health effects, using WEN by Chaz Dean (WCD) cleansing conditioners as a case study. WCD cleansing conditioner adverse event reports from January 2005 to December 2018 were abstracted from the CAERS database. Zero-inflated negative binomial regression models were used to analyze the rate of adverse events (WCD events/10,000 WCD cleansing conditioner units sold/month), adjusted for temporal trends in CAERS. Results There was a statistically significant higher rate of adverse event reporting after negative media coverage in December 2015 (IRR 16.71 [95% CI: 7.89-35.39]) when compared to the rate of adverse event reporting before December 2015. Conclusions This analysis highlights the importance of assessing potential external factors, such as negative news media coverage, that may alter reporting behaviors due to societal shifts in product-specific risk perception. Consideration of these factors in post-market surveillance programs would result in more comprehensive safety evaluations.
引用
收藏
页码:1849 / 1854
页数:6
相关论文
共 50 条
  • [41] Caution in making inferences from FDA's Adverse Event Reporting System
    Auerbach, Michael
    Kane, Robert C.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (11) : 922 - 923
  • [42] Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
    Dehua Zhao
    Xiaoqing Long
    Jiping Zhou
    Jisheng Wang
    [J]. Drugs in R&D, 2023, 23 : 403 - 409
  • [43] Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
    Zhao, Dehua
    Long, Xiaoqing
    Zhou, Jiping
    Wang, Jisheng
    [J]. DRUGS IN R&D, 2023, 23 (04) : 403 - 409
  • [44] Metoclopramide and tardive dyskinesia: A review of the FDA Adverse Event Reporting System.
    Shaffer, D
    Butterfield, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P24 - P24
  • [45] An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
    Hsin-wei Wang
    Alan M. Hochberg
    Ronald K. Pearson
    Manfred Hauben
    [J]. Drug Safety, 2010, 33 : 1117 - 1133
  • [46] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Zhao, Yibei
    Jiang, Huiming
    Xue, Lifen
    Zhou, Mi
    Zhao, Xiaobing
    Liu, Fei
    Jiang, Songjiang
    Huang, Jing
    Meng, Long
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (02) : 480 - 487
  • [47] Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
    Cheng, Connie
    Woronow, Daniel
    Nayernama, Afrouz
    Wroblewski, Tanya
    Jones, S. Christopher
    [J]. LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 3016 - 3017
  • [48] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
    Morris, Robert
    Ali, Rahinatu
    Cheng, Feng
    [J]. CURRENT DRUG TARGETS, 2024, 25 (07) : 454 - 464
  • [50] Performance of subgrouped proportional reporting ratios in the US food and drug administration (FDA) adverse event reporting system
    Dauner, Dan
    Zhang, Rui
    Adam, Terrence
    Leal, Eleazar
    Farley, Joel F.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 598 - 598